Download MendeleyDiscovery of Selective 4-Amino-pyridopyrimidine Inhibitors of MAP4K4 Using Fragment-Based Lead Identification and Optimization.
Crawford, T.D., Ndubaku, C.O., Chen, H., Boggs, J.W., Bravo, B.J., Delatorre, K., Giannetti, A.M., Gould, S.E., Harris, S.F., Magnuson, S.R., McNamara, E., Murray, L.J., Nonomiya, J., Sambrone, A., Schmidt, S., Smyczek, T., Stanley, M., Vitorino, P., Wang, L., West, K., Wu, P., Ye, W.(2014) J Med Chem 57: 3484-3493
- PubMed: 24673130 Search on PubMed
- DOI: https://doi.org/10.1021/jm500155b
- Primary Citation Related Structures:
4OBO, 4OBP, 4OBQ - PubMed Abstract:
Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) is a serine/threonine kinase implicated in the regulation of many biological processes. A fragment-based lead discovery approach was used to generate potent and selective MAP4K4 inhibitors. The fragment hit pursued in this article had excellent ligand efficiency (LE), an important attribute for subsequent successful optimization into drug-like lead compounds. The optimization efforts eventually led us to focus on the pyridopyrimidine series, from which 6-(2-fluoropyridin-4-yl)pyrido[3,2-d]pyrimidin-4-amine (29) was identified. This compound had low nanomolar potency, excellent kinase selectivity, and good in vivo exposure, and demonstrated in vivo pharmacodynamic effects in a human tumor xenograft model.
- Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States.
Organizational Affiliation:
